BIA Networking Lunch - Glasgow
** We regret to inform attendees that we have decided not to run this event. We hope to update with a new date soon.
Following close monitoring of the situation around the COVID-19 outbreak, all BIA events week commencing 16 March have been cancelled or moved. **
Thursday 19 March 2020
BIA is proud to host our annual regional event in Scotland in collaboration with Life Science Scotland. This year, we will be holding it in Glasgow’s Corinthian Club on 19 March.
We will be hosting a workshop and panel discussion on the topic of “Digital transformation for discovery and manufacturing”. Please come and join us to see how organisations in Scotland are at the cutting edge of the digital revolution for life sciences, and learn more about how you can apply this to your own organisation.
11.15: Workshop – “Accelerating Science with Software Models - Examples of Successful Collaborations”
Rob Innes and Michelle Waddell of Wyoming Interactive will co-present case studies with organisations they have collaborated with:
Blair Johnson, CMAC
Mazdak Salvati, Roslin Innovation Centre
12.15: Lunch and networking
13.15: BIA update - Steve Bates, CEO, BIA
13:30: Presentations with Q&A
"Riding the wave of digital chemistry to improve outcome and reproducibility" - Mark Warne, Deepmatter
“Developments in Digital Technologies and Microfactories” - Andrea Johnston, CMAC
“Advanced digital solutions in the pharmaceutical industry” - Dave Tudor, MMIC
14:30: Networking, tea/coffee provided
Address: Corinthian Club, 191 Ingram Street, Merchant City, Glasgow, G1 1DA
The Corinthian Club is housed within one of Glasgow’s most impressive buildings at 191 Ingram Street, a former bank and high court.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Dr Blair Johnston is a Senior Lecturer in Computational Modelling at the Strathclyde Institute of Pharmacy and Biomedical Sciences. He teaches on the Masters of Pharmacy, Pharmaceutical Analysis, Clinical Pharmacy and Chemistry with Drug Discovery degrees.
His group has research interests in five broad areas: drug discovery, molecular structure simulation, machine learning and prediction, data analysis, and web-enabled science and collaboration tools. In the vast majority of the research, the group work closely with experimental scientists in the design and execution of collaborative research to realise the full potential of their laboratory data. This combination of experiment and theory often provides unique insight into the systems being studied.
After graduating as a veterinarian with a keen interest in livestock data and herd health management, Mazdak obtained his PhD in biomedical sciences in 2013. He started to work as a postdoctoral researcher at The Royal Veterinary College from 2013-2018 in molecular biology and bioinformatics. During this time he worked with a variety of livestock genomics research groups across Europe and the United States as one of the bioinformaticians of the Genotype plus Environment consortium. He is currently working as the core scientist within the ruminants functional genomics lab, at the Roslin Institute, with a focus on projects running as part of the Centre of Tropical Livestock Genetics and Health and the Functional Annotation of Animal Genomes project. He has a vested interest in functional programming in R, Python and bash scripting for developing analytical pipelines. His research interests could be summarised as transcriptomics and allele specific expression profiling, multidimensional data analytics, livestock informatics and big data visualisations, and distributed computing.
Mark Warne, was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of Open Orphan plc and Ixico plc.
A solid-state chemist with expertise in the area of crystallisation and physical form screening in terms of identifying new polymorphs, solvates or co-crystals and performing full physical analyses of crystalline forms. Andrea also has a keen interest in the use of chemoinformatics in both rationalising experiments for physical form screening and determining which parameters are governing crystalline outcome. Responsible for planning and implementation of Hub Research activities; Manages Hub and Postgraduate Development staff.
Dave joined CPI in January 2019 as Managing Director for the Medicines Manufacturing Innovation Centre (MMIC).
The MMIC is a collaboration between industry, academia and government. CPI is working together with the University of Strathclyde, AstraZeneca and GSK. With government support from Scottish Enterprise and Innovate UK, the MMIC will be located in Renfrewshire, Scotland.
The MMIC is a unique facility to enable new and disruptive pharmaceutical manufacturing technologies to be proven at scale in a GMP-capable environment. This will speed next-generation process adoption with reduced risk, cost and time, and provide a unique environment for the training of personnel in the techniques of future manufacturing processes.
Prior to this Dave worked for GSK, joining in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience with the company carrying out a number of Technical, Compliance and Manufacturing leadership roles, before becoming VP Head of GMS Strategy in 2017, with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.
Dave is married with 4 children and lives in Ayrshire. He enjoys all sports, particularly football, is a keen reader of Scottish history and cooks to relax.
Thank you to our partner